DBT calls for proposals under ‘Proven vaccine technologiesfor rapid response against novel coronavirus, 2019-nCoV’
- by Team ABLE - 11 Feb, 2020
The objective of this Call for Proposals is to rapidly develop and manufacture a proven vaccine approach that can be used against the 2019-nCoV. This call aims to complement CEPI’s 2019-nCoV portfolio and candidates should have large-scale manufacturing capabilities for 2019-nCoV.
CEPI is announcing a funding opportunity for the development of vaccine against the 2019 novel corona virus, 2019-nCoV. This call is open for 2 weeks. The deadline for application is February 14, 15:00 CET.
The call may be extended or amended depending on programmatic need. CEPI reviews and evaluates applications on their merits and in the context of stated eligibility criteria and CEPI's overall project portfolio. Regardless of eligibility at any stage of a funding call, CEPI reserves the right to consider and to decline proposals in its sole discretion.
The organization must be willing to transfer their vaccine technology to a global network of large-scale manufacturing. Vaccine candidates will be evaluated against several criteria to assess the utility of the product candidate and the speed with which it can be developed and tested and induce a 2019-nCoV virusspecific response.
The technology will also be judged against its proven ability to be manufactured at large scale. The suggested vaccine-technology performance will be considered towards the following guidelines: • Speed from sequence of pathogen availability to clinical-trial testing • Number of doses needed – to gain clinical benefit • Scale of manufacturing o In the current situation CEPI will be aiming for a capacity of production of millions of doses Supporting the development of vaccines that can prevent or stop an outbreak is a key part of CEPI’s mission.
An equally critical part of the mission is to ensure that the vaccine is available and equally accessible to those who need them. Thus, in addition to the criteria of speed and versatility the vaccine technology must be able to be delivered to individuals easily in an outbreak setting and to be at a cost of goods that does not preclude broad access.
This call is open for 2 weeks. The deadline for application is February 14, 15:00 CET.